Alemtuzumab toxicity

NK cells, monocytes, macrophages, and a small population of granulocytes. Currently, alemtuzumab is approved for the treatment of -cell chronic lymphocytic leukemia in patients who have been treated with alkylating agents and have failed fludarabine therapy. Alemtuzumab appears to deplete leukemic and normal cells by direct antibody-dependent lysis. Patients receiving this antibody become lymphopenic and may also become neutropenic, anemic, and thrombocytopenic. As a result patients should be closely monitored for opportunistic infections and hematologic toxicity. 

Alemtuzumab ADCC CDC apoptosis Escalation 3, 10, 30 mg/m IV 3 times per week followed by 30 mg/m 3 times per week for 4 to 12 weeks Infusion-related toxicity, T-cell depletion with increased infection hematopoietic suppression pancytopenia... 

Alemtuzumab CD52 B-cell chronic lymphocytic leukemia Infections, hematologic toxicity, infusion reactions, hypersensitivity... 

---